1-Phenyl-3-(piperidin-2-ylmethyl)imidazolidin-2-one hydrochloride

Catalog No. :
ACNDRA198
CAS No. :
1257326-24-1
Molecular Formula :
C15H22ClN3O
Molecular Weight :
295.81

IUPAC Name:1-phenyl-3-(piperidin-2-ylmethyl)imidazolidin-2-one hydrochloride

1-Phenyl-3-(piperidin-2-ylmethyl)imidazolidin-2-one hydrochloride structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
250mg97%$69.00Login to see priceIn stockInquiry
1g97%$235.00Login to see priceIn stockInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Name1-Phenyl-3-(piperidin-2-ylmethyl)imidazolidin-2-one hydrochloride
IUPAC Name1-phenyl-3-(piperidin-2-ylmethyl)imidazolidin-2-one hydrochloride
MDL No.MFCD18086910
Molecular FormulaC15H22ClN3O
Molecular Weight295.81
SMILESO=C1N(CC2NCCCC2)CCN1C3=CC=CC=C3.[H]Cl
InChI KeyBYJUVPWUMBVSTK-UHFFFAOYSA-N
Synonym4,5-Dihydro-1-phenyl-3-(2-piperidinyl)methylimidazol-2(1H)-one;GSK 789472 hydrochloride;1-Phenyl-3-(piperidin-2-ylmethyl)imidazolidin-2-one hydrochloride;5-Dihydro-1-phenyl-3-(2-piperidinyl)methylimidazol-2(1H)-one;GSK-789472 HCl;4,5-dihydro-1-phenyl-3- (2-piperidinyl) methylimidazole-2 (1H) - one;Dopamine D2 receptor agonist-3
CAS No.1257326-24-1
PubChem CID57347570

Safety Data

Pictogram
Harmful or irritant
Signal Word
Achtung
Hazard Statement(s)
H302-H315-H319-H335
Precautionary Statement(s)
P261-P280-P301+P312-P302+P352-P305+P351+P338

Synthetic Route by SureRoute

1. ACNDRA198 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACNDRA198 route product structure diagram
    ACNDRA1981257326-24-1 In Stock
Inquiry

2. ACNDRA198 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. reactant_1 route compound structure diagram
    --
  2. Then
  3. ACNDRA198 route product structure diagram
    ACNDRA1981257326-24-1 In Stock
Inquiry

Comments (0)